Glucosylceramide Synthase Inhibitors Pipeline Insight Report 2021 Featuring Idorsia Pharmaceuticals & Sanofi and Lucerastat, Venglustat & Sinbaglustat – ResearchAndMarkets.com
April 15, 2021DUBLIN–(BUSINESS WIRE)–The “Glucosylceramide Synthase Inhibitors – Pipeline Insight, 2021” drug pipelines has been added to ResearchAndMarkets.com’s offering.
This “Glucosylceramide synthase inhibitors – Pipeline Insight, 2021,” report provides comprehensive insights about 5+ companies and 5+ pipeline drugs in Glucosylceramide synthase inhibitors pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Report Highlights
The companies and academics are working to assess challenges and seek opportunities that could influence Glucosylceramide synthase inhibitors R&D. The therapies under development are focused on novel approaches for Glucosylceramide synthase inhibitors.
Glucosylceramide synthase inhibitors Emerging Drugs Chapters
This segment of the Glucosylceramide synthase inhibitors report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Glucosylceramide synthase inhibitors Emerging Drugs
Lucerastat: Idorsia Pharmaceuticals
Lucerastat inhibits glycolipid biosynthesis. Lucerastat is an orally bioavailable inhibitor of glucosylceramide synthase. Lucerastat is being developed by the biopharmaceutical company Idorsia for the treatment of Fabry disease. It is currently in Phase III stage of development. It acts as Glucosylceramide synthase inhibitor. In 2018, Lucerastat has received Orphan Drug designation in the US and in the EU for Fabry disease.
Venglustat: Sanofi
Venglustat is an investigational oral glucosylceramide synthase inhibitor in development for multiple diseases with disruptions in the GSL metabolic pathway. These diseases include three lysosomal storage disorders: Gaucher disease type 3, Fabry disease and GM2 gangliosidosis as well as autosomal dominant polycystic kidney (ADPKD) disease and GBA-associated Parkinson’s disease.
The FDA has granted Fast Track designation for the development of venglustat as an investigational therapy for the treatment of Gaucher disease type 3, Fabry disease and GM2 gangliosidosis. Sanofi has been granted Orphan Drug Designation for venglustat in Europe and the U.S. for treatment of patients with Fabry disease, ADPKD, Gaucher disease and GM2 gangliosidosis.
Glucosylceramide synthase inhibitors: Therapeutic Assessment
This segment of the report provides insights about the different Glucosylceramide synthase inhibitors drugs segregated based on following parameters that define the scope of the report, such as:
Major Players working on Glucosylceramide synthase inhibitors
There are approx. 5+ key companies which are developing the Glucosylceramide synthase inhibitors. The companies which have their Glucosylceramide synthase inhibitors drug candidates in the most advanced stage, i.e. Phase III include, Idorsia Pharmaceuticals.
Key Players
- Idorsia Pharmaceuticals
- Sanofi
Key Products
- Lucerastat
- Venglustat
- Sinbaglustat
Key Topics Covered:
Introduction
Executive Summary
Glucosylceramide synthase inhibitors: Overview
- Structure
- Mechanism of Action
Pipeline Therapeutics
- Comparative Analysis
Therapeutic Assessment
- Assessment by Product Type
- Assessment by Stage and Product Type
- Assessment by Route of Administration
- Assessment by Stage and Route of Administration
- Assessment by Molecule Type
- Assessment by Stage and Molecule Type
Glucosylceramide synthase inhibitors- Analytical Perspective
In-depth Commercial Assessment
- Glucosylceramide synthase inhibitors companies’ collaborations, Licensing, Acquisition -Deal Value Trends
Glucosylceramide synthase inhibitors Collaboration Deals
- Company-Company Collaborations (Licensing / Partnering) Analysis
- Company-University Collaborations (Licensing / Partnering) Analysis
Late Stage Products (Phase III)
- Comparative Analysis
Lucerastat: Idorsia Pharmaceuticals
- Product Description
- Research and Development
- Product Development Activities
Mid Stage Products (Phase II)
- Comparative Analysis
Drug Name: Company Name
- Product Description
- Research and Development
- Product Development Activities
Early Stage Products (Phase I)
- Comparative Analysis
Sinbaglustat: Idorsia Pharmaceuticals
- Product Description
- Research and Development
- Product Development Activities
Pre-clinical and Discovery Stage Products
- Comparative Analysis
Drug Name: Company Name
- Product Description
- Research and Development
- Product Development Activities
Inactive Products
- Comparative Analysis
Glucosylceramide synthase inhibitors Key Companies
Glucosylceramide synthase inhibitors Key Products
Glucosylceramide synthase inhibitors- Unmet Needs
Glucosylceramide synthase inhibitors- Market Drivers and Barriers
Glucosylceramide synthase inhibitors- Future Perspectives and Conclusion
Glucosylceramide synthase inhibitors Analyst Views
Glucosylceramide synthase inhibitors Key Companies
Appendix
Companies Mentioned
- Idorsia Pharmaceuticals
- Sanofi
For more information about this drug pipelines report visit https://www.researchandmarkets.com/r/s23qd2
Contacts
ResearchAndMarkets.com
Laura Wood, Senior Press Manager
[email protected]
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900